Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2022, with a report date of January 26, 2022. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Type | Instrument | Price (USD) | Volume | Date |
|---|---|---|---|---|
| Executive Supplemental Savings Plan | ADSs | $44.38 | 1,055.97 | 2022-01-24 |
| 401(k) Plan | ADSs | $44.38 | 189.00 | 2022-01-24 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions of American Depositary Shares (ADSs) by Dr. H. Barron, Chief Scientific Officer and President, R&D, on the New York Stock Exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a specific transaction.
Key Facts for Investor Verification
- Insider Activity: Dr. H. Barron acquired a total of 1,244.97 ADSs on January 24, 2022.
- Transaction Price: Both transactions occurred at a price of $44.38 per ADS.
- Account Types: Acquisitions were made through the GSK Executive Supplemental Savings Plan and the GSK 401(k) Plan.
- Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.